0001567619-20-014921.txt : 20200812 0001567619-20-014921.hdr.sgml : 20200812 20200812163259 ACCESSION NUMBER: 0001567619-20-014921 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200810 FILED AS OF DATE: 20200812 DATE AS OF CHANGE: 20200812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DEMANE MICHAEL F CENTRAL INDEX KEY: 0001174533 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36715 FILM NUMBER: 201095855 MAIL ADDRESS: STREET 1: MEDTRONIC INC STREET 2: 710 MEDTRONIC PKWY, MS LC310 CITY: MINNEAPOLIS STATE: MN ZIP: 55432-5604 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEVRO CORP CENTRAL INDEX KEY: 0001444380 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 562568057 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1800 BRIDGE PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-251-0005 MAIL ADDRESS: STREET 1: 1800 BRIDGE PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 4 1 doc1.xml FORM 4 X0306 4 2020-08-10 0 0001444380 NEVRO CORP NVRO 0001174533 DEMANE MICHAEL F C/O NEVRO CORP. 1800 BRIDGE PARKWAY REDWOOD CITY CA 94065 1 0 0 0 Common Stock 2020-08-10 4 S 0 30469 134.3417 D 401039 D Common Stock 2020-08-10 4 S 0 19785 135.5825 D 381254 D Common Stock 2020-08-10 4 S 0 24208 136.1837 D 357046 D Common Stock 2020-08-10 4 S 0 3813 138.4390 D 353233 D Common Stock 2020-08-10 4 S 0 2337 138.8748 D 350896 D Common Stock 2020-08-10 4 S 0 2828 140.11 D 348068 D Common Stock 2020-08-10 4 S 0 1626 134.4178 D 40928 I See footnote Common Stock 2020-08-10 4 S 0 1474 135.6428 D 39454 I See footnote Common Stock 2020-08-10 4 S 0 1000 136.373 D 38454 I See footnote Common Stock 2020-08-10 4 S 0 400 138.6975 D 38054 I See footnote Common Stock 50000 I See footnote The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $133.84 to $134.79, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Includes 1,376 restricted stock units. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $134.85 to $135.84, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $135.85 to $136.79, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $137.74 to $138.63, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $138.74 to $139.17, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $133.95 to $134.82, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Shares held by Catherine Q. DeMane Trustee, Michael F. DeMane 2012 Irrevocable Trust U/A/D July 26, 2012. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $134.96 to $135.95, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $135.96 to $136.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $138.57 to $139.06, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Shares held by Michael DeMane Trustee, Michael F. DeMane 2016 Retailed Annuity Trust U/A/D May 22, 2017. /s/ Kashif Rashid, as Attorney-in-Fact for Michael DeMane 2020-08-12